Guildford, UK, 17 December 2015: ReNeuron Group plc (the “Company”) (AIM: RENE), a leading UK-based stem cell therapy development company, is pleased to announce that it has held the inaugural meeting of its newly-established Scientific Advisory Board (“SAB”), which comprises nine leading academics and industry executives with a world-class breadth of expertise across the Company’s areas of operation. The meeting was chaired by Dr Mike Owen, who was recently appointed as a Non-executive Director of the Company.